Amalgamated Bank’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Amalgamated Bank’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-12,379	Closed	-$250K	–	2189
2021 Q3	$250K	Sell	12,379 -624	-5%	-$17.2K	﹤0.01%	1912
2021 Q2	$485K	Buy	13,003 +3,635	+39%	+$111K	﹤0.01%	1661
2021 Q1	$240K	Sell	9,368 -933	-9%	-$23.8K	0.01%	1385
2020 Q4	$227K	Buy	10,301 +204	+2%	+$4.49K	0.01%	1378
2020 Q3	$182K	Sell	10,097 -302	-3%	-$6.25K	0.01%	1331
2020 Q2	$264K	Buy	+10,399	New	+$224K	0.01%	1182
2020 Q1	–	Sell	-9,700	Closed	-$214K	–	1817
2019 Q4	$214K	Buy	+9,700	New	+$195K	﹤0.01%	1612

Other funds holding DRNA

CAM

Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

Amalgamated Bank's DRNA Position: Q4 2021 in Review

Amalgamated Bank sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 12,379 shares — an estimated $250K sold.

Amalgamated Bank first reported a position in DRNA in Q4 2019 and held it in 7 quarters. The position peaked at $485K in Q2 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

Amalgamated Bank reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Amalgamated Bank sold 12,379 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $250K.
Amalgamated Bank first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2019 and held it in 7 quarters.
Amalgamated Bank's Dicerna Pharmaceuticals, Inc. position peaked at $485K in Q2 2021.
1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on Amalgamated Bank's 13F filing for Q4 2021, filed 15 Feb 2022.